- Analysis of Medicare fee-for-service administrative data indicates that testosterone use is higher in men with coronary artery disease (CAD) compared with men without CAD.
Why this matters
- The FDA and Endocrine Society have issued safety warnings about increased cardiovascular risk associated with testosterone use.
- Throughout the study period, testosterone use was consistently higher for men with CAD compared with men without CAD (2.0% vs 1.6% in 2016).
- Off-label prescription testosterone use peaked in 2013 (3.2% of men with CAD; 2.4% of men without CAD).
- The proportion of men with Part D prescription testosterone fills subject to prior authorization was 21% in 2012 and 49% in 2016.
- In the 4 regions with the highest testosterone use, use ranged from 4.4% to 7.0% in 2016.
- In the 14 regions with the lowest testosterone use, use ranged from 0.5% to 1.0% in 2016.
- A 40% random sample of Medicare fee-for-service administrative data from January 1, 2007, to December 31, 2016, was used to generate an annual cohort of men aged ≥50 years who were analyzed for CAD status and testosterone use.
- Funding: Agency for Healthcare Research and Quality Comparative Health System Performance Initiative.
- Use of claims data that may have inaccuracies.